Zhou Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhou Hong has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Daofeng Chen
Fudan University
1 shared publication - Guoqi Yuan
Department of Natural Medicine, School of Pharmacy, Fudan University, Shanghai 201203, China
1 shared publication - Haiyan Zhu
Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, China
1 shared publication - Hao Yang
School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China
1 shared publication - Liming Zhang
School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China
1 shared publication - Lishuang Zhou
School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang 524023, China
1 shared publication
Latest Publications
- Open Access
Preliminary Structural Characterization of an Anti-Inflammatory Polysaccharide from Lysimachia christinae and Its Preventive Effect on Lipopolysaccharide-Induced Acute Liver Injury in Mice
An acidic heteropolysaccharide, named LCP-90-3, with a relative molecular weight of 14.02 kDa, was isolated and purified from the traditional heat-clearing Chinese medicine, Lysimachia christinae Hance. The monosaccharide residue analysis indicated that LCP-90-3 was composed of glucuronic acid, mannose, and arabinose in a molar ratio of 79.2: 3.6: 17.2. Linkage analysis further indicated that LCP-90-3 was mainly composed of 1,4-GlcpA, 1,4,6-GlcpA, 1,2-Araf, T-Manp, 1,3-Araf, and 1,4-Manp residues. Furthermore, LCP-90-3 demonstrated potent anti-inflammatory activity by significantly inhibiting the secretion of nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in lipopolysaccharide (LPS)-treated ANA-1 cells. Interestingly, oral administration of LCP-90-3 at doses of 20, 40, and 80 mg/kg effectively mitigated LPS-induced acute liver injury in vivo by suppressing the overexpression of inflammatory mediators (NO, TNF-α, and IL-6), aminotransferases (ALT and AST) in serum, and markers of antioxidant capacity (MDA, CAT, and SOD) in the liver. Overall, these findings highlight LCP-90-3 as a novel leading polysaccharide for new drug candidate development against liver injury through modulation of inflammatory responses and oxidative stress.
Open AccessPreliminary Structural Characterization of an Anti-Inflammatory Polysaccharide from Lysimachia christinae and Its Preventive Effect on Lipopolysaccharide-Induced Acute Liver Injury in Mice
An acidic heteropolysaccharide, named LCP-90-3, with a relative molecular weight of 14.02 kDa, was isolated and purified from the traditional heat-clearing Chinese medicine, Lysimachia christinae Hance. The monosaccharide residue analysis indicated that LCP-90-3 was composed of glucuronic acid, mannose, and arabinose in a molar ratio of 79.2: 3.6: 17.2. Linkage analysis further indicated that LCP-90-3 was mainly composed of 1,4-GlcpA, 1,4,6-GlcpA, 1,2-Araf, T-Manp, 1,3-Araf, and 1,4-Manp residues. Furthermore, LCP-90-3 demonstrated potent anti-inflammatory activity by significantly inhibiting the secretion of nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in lipopolysaccharide (LPS)-treated ANA-1 cells. Interestingly, oral administration of LCP-90-3 at doses of 20, 40, and 80 mg/kg effectively mitigated LPS-induced acute liver injury in vivo by suppressing the overexpression of inflammatory mediators (NO, TNF-α, and IL-6), aminotransferases (ALT and AST) in serum, and markers of antioxidant capacity (MDA, CAT, and SOD) in the liver. Overall, these findings highlight LCP-90-3 as a novel leading polysaccharide for new drug candidate development against liver injury through modulation of inflammatory responses and oxidative stress.